Pitavastatin

1. Pitavastatin lowers the risk of cardiovascular events in humans.

   “In the REPRIEVE study, treatment with pitavastatin was shown to reduce the rate of first cardiovascular events among individuals with HIV receiving antiretroviral therapy.”

   Reviewreceiving antiretroviral therapy

   Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE · Biomolecules · 29 Aug 2026

Cardiovascular events →